USANA (USNA) to Report Q2 Earnings: What's in the Cards?
Zacks Investment Research | Jul 17, 2020 03:16AM ET
USANA Health (NYSE:USNA) Sciences Inc. USNA is scheduled to report second-quarter 2020 results on Jul 21, aftermarketclose.
The company flaunts a mixedearningssurprise history, having surpassed expectations in three of the trailing four quarters by 63.14%, on average. In the last reported quarter, the company delivered an earnings surprise of 115.79%.
Shares of USANA have gained 12.9% in the year so far against the industry ’s decline of 5.6%.
Let's see how things are shaping up for this announcement.
Factors to Consider
USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to associates and preferred customers throughout the United States, Canada, and many more countries.
USANA expects the COVID-19 pandemic to affect the operational results for the entire year. The results were also affected by the same in the first quarter and the trend most likely prevailed in the second quarter.
For the second quarter, the company had projected sales in the range of $250 million. The ongoing pandemic has most likely impacted both sales and earnings in the second quarter.
In July 2020, USANA received another seal of approval from third-party tester, ConsumerLab.com, for its flagship supplement, USANA CellSentials. This is the highly regardedseal of approval from the ConsumerLab.com. USANA CellSentials is unlike any other nutritional supplement inthe market because of its unique ability to activate the cells' innate natural responses to protect and renew themselves. The seal is likely to have ledto increased sales for the company in the second quarter.
In the same month, USANA’s CopaPrime+ study, which was conducted in collaboration with Deakin University in Australia and Nanyang Technological University in Singapore, showed that the study supports three cognitive measures—working memory and accuracy, attention speed and response time, and brain efficiency—only 45 minutes after participants took a single dose.
The CopaPrime+ study showed that participants who took the supplement had significant differences in working memory and accuracy, speed of attention and response time, and brain efficiency over those who were given placebo. With these results, the company reiterated its decision to formulate CopaPrime+ with three nootropics — American ginseng, bacopa monnieri, and coffee-fruit extract. We expect an update on this in the second quarter.
Get The News You Want
USANA Health Sciences, Inc. Price and EPS Surprise
USANA Health Sciences, Inc. Quote
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for USANA this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: USANA has an Earnings ESP of 0.0%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter .
Zacks Rank: The company carries a Zacks Rank #1.
Stocks to Consider
Here are some biotech stocks with the right mix of elements to beat on earnings this time around:
Theravance Biopharma (NASDAQ:TBPH) Inc. TBPH has an Earnings ESP of +20.95% and a Zacks Rank #3.
United Therapeutics (NASDAQ:UTHR) Corp. UTHR has an Earnings ESP of +9.13% and a Zacks Rank of 3.
Ionis Pharmaceuticals (NASDAQ:IONS), Inc. IONS has an Earnings ESP of +30.77% and aZacks Rank of 3.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.